

HEMISPHERX BIOPHARMA INC

Form 8-K

October 03, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  
October 2, 2013

HEMISPHERX BIOPHARMA, INC.  
(Exact name of registrant as specified in its charter)

|   |  |   |
|---|--|---|
| Delaware<br>(state or other juris-<br>diction of incorporation) | 0 27072<br>(Commission<br>File Number) | 52-0845822<br>(I.R.S. Employer<br>Identification No.) |
|---|--|---|

|   |                     |
|---|---------------------|
| 1617 JFK Boulevard, Suite 500, Philadelphia, PA<br>(Address of principal executive offices) | 19103<br>(Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code: (215) 988-0080

1617 JFK Boulevard, Suite 660, Philadelphia, PA 19103  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Section 8.01 - Other Events

On October 3, 2013, Hemispherx Biopharma, Inc. announced that its Board of Directors has decided not to seek Stockholder approval regarding the proposed HEMISPHERx 2013 Equity Incentive Plan and has withdrawn this proposal from the agenda for its Annual Meeting scheduled for October 18, 2013.

The Company's Board of Directors has removed Proposal 4 from Stockholder consideration for the upcoming Annual Meeting. Therefore, any votes cast regarding Proposal 4 will not be calculated nor reported.

Item 9.01. Financial Statements and Exhibits.

| (d) Exhibits: | Description                          |
|---------------|--------------------------------------|
| 99.1          | Press release dated October 3, 2013. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX BIOPHARMA, INC.

October 3, 2013

By: /s/ Charles T. Bernhardt  
Charles T. Bernhardt  
Chief Financial Officer